Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement.
RemeGen Co., Ltd. has released its unaudited financial data for the first quarter of 2025, prepared according to Chinese accounting principles. The report has been reviewed by the company’s audit committee but not by independent auditors, and stakeholders are advised to exercise caution when dealing with the company’s securities.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, with a market presence on the Shanghai Stock Exchange and the Hong Kong Stock Exchange.
YTD Price Performance: 201.74%
Average Trading Volume: 6,991,215
Technical Sentiment Signal: Sell
Current Market Cap: HK$27.68B
See more data about 9995 stock on TipRanks’ Stock Analysis page.